News

Sweden boosts life sciences
Enlarge image

ResearchSweden

Sweden boosts life sciences

21.09.2012 - The Swedish Government is set to boost its life sciences industry with a US$320m investment over the next four years.

Swedish Prime Minister Fredrik Reinfeldt confirmed the country’s largest ever investment into the life sciences. Speaking at SciLifeLab in Stockholm, a major research infrastructure project aimed at maintaining the country’s position in protein science, Reinfeldt announced a package of measures totalling US$1.7bn over the next four years, of which $ 320 million is devoted to life sciences. According to the decision of Reinfeldt and four ministers, the budget of SciLifeLab will be doubled to a total of US$100m. The centre combines state-of-the-art research infrastructure with a broad knowledge in translational medicine and molecular bioscience in order to translating discoveries into both tools and therapies. Additionally, US$220m will be pumped into drug discovery, clinical research, antibiotic resistance research, health in aging and the use of patient registries. 

Most of the money will be invested into the Stockholm-Uppsala biocluster which is home to more than 50% of Sweden’s thriving life science companies. Stockholm-Uppsala Life Sciences CEO Ola Bjorkman welcomed the Prime Minister’s commitment: “In our recently published report, we pointed out the ambitious, future plans for further strengthening the life science sector in Stockholm-Uppsala, thereby ensuring that the region remains a truly global life science cluster. In particular, the investment in SciLifeLab with its cutting edge research infrastructure combined with parallel investments in drug discovery, clinical research and the use of patient registries open new avenues for developing more personalised and outcome-orientated healthcare.” 

According to a report published this August, the Stockholm-Uppsala region is one of the largest clusters in Europe. According to official sources on limited public companies, the region is home to 633 companies, which employ 23,376 staff and had a combined turnover of €20bn in 2010. More than 16,000 employees (70%) work with R&D-orientated companies while 30% are distributors. Pharmaceutical companies such as AstraZeneca (5,600 jobs) employ 13,500 staff followed by medical technology firms 4,700, biotech tools & supply enterprises such as GE Healthcare (1,225 jobs) with 2,750 (12%), CROs and other services with 1,250 staff and diagnostics companies with 1,050 jobs.

http://www.european-biotechnology-news.com/news/news/2012-03/sweden-boosts-life-sciences.html

AwardFinlandEU

27.05.2016 The Finnish Technology Academy has awarded US-American innovator Frances Arnold the 2016 Millennium Technology Prize, worth €1m. Arnold is a pioneer in the field of directed evolution.

OncologyUK

26.05.2016 BigDNA relaunches as Iceni Pharmaceuticals with the aim to develop repurposed and reformulated cancer therapies. First order of business: repurpose Merck Serono’s cilengitide as a multiple myeloma treatment.

MicrobiomeFranceDenmarkEU

24.05.2016 One of the pioneering companies developing pharmaceuticals and diagnostics based on the gut microbiome, Enterome Bioscience, has raised €14.5m in a Series C financing round. Among the investors were Seventure and Lundbeckfond as well as Nestlé.

AntibioticsEUUKItaly

20.05.2016 The long awaited global review on antimicrobial resistance by economist Lord Jim O’Neill has been published. It sets out an action plan to defeat superbugs with a huge awareness campaign and rapid diagnostics to be used before antibiotics are prescribed.

LicensingGermanyIrelandSwitzerland

18.05.2016 Bayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one of the inventors.

M&AGermany

17.05.2016 Newly rebranded Siemens Healthcare has entered the field of molecular testing for cancers with the acquisition of Cologne-based NEO New Oncology.

FinancingUK

11.05.2016 Newly spun out company OxStem has raised £16.9m (€21.5m) to develop regenerative meds for the treatment of age-related disease. It is the largest financing for an Oxford spin-out – or any UK academic spin-out – to date.

FinancingSwitzerland

09.05.2016 Swiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and diagnostic product pipeline in Alzheimer’s disease. The news follows a recently announced R&D collaboration with Biogen.

FinancingSpain

04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

Open InnovationFrance

03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Aachen

Biomedica 2016

Basel (CH)

Chemspec Europe 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • PLETHORA (UK)3.38 GBP12.67%
  • ALMIRALL (E)14.43 EUR7.93%

FLOP

  • 4SC (D)2.59 EUR-20.31%
  • NEUROVIVE PHARMACEUTICAL AB (S)5.25 SEK-4.55%
  • FORMYCON (D)20.15 EUR-4.37%

TOP

  • GALAPAGOS (B)51.86 EUR30.6%
  • NICOX (F)11.00 EUR26.0%
  • GENMAB (DK)1177.00 DKK21.2%

FLOP

  • 4SC (D)2.59 EUR-24.5%
  • MOBERG PHARMA (S)38.00 SEK-23.1%
  • BIONOR PHARMA (N)0.68 NOK-20.0%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)30.60 SEK1913.2%
  • NICOX (F)11.00 EUR485.1%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)5.25 SEK-89.1%
  • BB BIOTECH (D)44.03 EUR-84.7%
  • BIOTEST (D)17.15 EUR-78.0%

No liability assumed, Date: 27.05.2016